Heard on the Street: Novo Nordisk and Pfizer are showing some desperation in their gloves-off fight for the obesity-drug assets of Metsera

Core Insights - Novo Nordisk and Pfizer are engaged in a competitive struggle for the obesity-drug assets of Metsera, indicating a high level of interest and potential value in this market [1] Company Analysis - Novo Nordisk is demonstrating aggressive tactics in its pursuit of Metsera's obesity-drug assets, reflecting its commitment to expanding its portfolio in the obesity treatment sector [1] - Pfizer is also showing signs of desperation in this competition, suggesting that the obesity-drug market is becoming increasingly critical for major pharmaceutical companies [1] Industry Trends - The competition for obesity-drug assets highlights the growing importance of obesity treatments in the pharmaceutical industry, as companies seek to capitalize on the rising demand for effective weight management solutions [1]